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aureus (MRSA) surveillance
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Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a human pathogen, representing an infection 
control challenge. Conventional MRSA screening takes up to three days, therefore development of rapid detection is 
essential. Real time-PCR (rt-PCR) is the fastest method fulfilling this task. All currently published or commercially 
available rt-PCR MRSA assays relay on single or double-locus detection. Double-locus assays are based on 
simultaneous detection of mecA gene and a S. aureus-specific gene. Such assays cannot be applied on clinical samples, 
which often contain both coagulase-negative staphylococci (CoNS) and S. aureus, either of which can carry mecA. 
Single-locus assays are based on detection of the staphylococcal cassette chromosome mec (SCCmec) element and 
the S. aureus-specific orfX gene, assuming that it is equivalent to mecA detection.
Findings: Parallel evaluation of several published single and double-locus rt-PCR MRSA assays of 150 pure culture 
strains, followed by analysis of 460 swab-derived clinical samples which included standard identification, susceptibility 
testing, followed by PCR detection of staphylococcal suspected isolates and in-PCR mixed bacterial populations 
analysis indicated the following findings.
Pure cultures analysis indicated that one of the single-locus assay had very high prevalence of false positives (Positive
predictive value = 77.8%) and was excluded from further analysis. Analysis of 460 swab-derived samples indicated
that the second single-locus assay misidentified 16 out of 219 MRSA's and 13 out of 90 methicillin-sensitive S. aureus's
(MSSA) were misidentified as MRSA's. The double-locus detection assay misidentified 55 out of 90 MSSA's. 46 MSSA
containing samples were misidentified as MRSA and 9 as other than S. aureus ending with low positive predicted
value (<85%) and very low specificity (<62%).
Conclusion: The results indicate that high prevalence of false-positive and false-negative reactions occurs in such 
assays.
Introduction
Staphylococci are ubiquitous colonizers of the skin and
mucous membranes. Among them, Staphylococcus
aureus is the most pathogenic species and a leading cause
of several life-threatening diseases [1]. S. aureus repre-
sents a major public health threat, as MRSA strains are
the leading cause of nosocomially acquired infections.
MRSA infections represent a challenge to both infection
control and treatment strategies, resulting in increased
morbidity, mortality, length of hospitalization and health
care costs [2-4]. Conventional MRSA screening takes up
to three days, during which patients and staff carriers can
spread MRSA. Development of rapid accurate detection
techniques should contribute to the prevention of trans-
mission. rt-PCR is the fastest method fulfilling this task.
All currently published or commercially available rt-
PCR  M RS A  d e t ect i o n  as s a y s  r e l y  o n  s i n g l e  o r  d o u b l e -
locus detection. Double-locus assays are based on simul-
taneous detection of the mecA gene and a S. aureus-spe-
cific gene, such as Sa442  [5]. However, they cannot
differentiate between MRSA and a mixture of methicil-
lin-sensitive S. aureus (MSSA) and methicillin-resistant
coagulase-negative staphylococci (MR-CoNS). As more
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than 80% of nasal swabs contain staphylococci, and 70-
80% of CoNS are MR-CoNS [1,6], many MSSA-contain-
ing samples result in a pseudo-MRSA genotype ending
with a low positive predictive value (PPV) [6]. Single-
locus assays are based on detection of the right extremity
of the staphylococcal cassette chromosome mec  (SCC-
mec) element assuming this is equivalent to mecA detec-
tion [7,8]. These assays include the first commercial test
for MRSA detection that has been approved by the U.S.
Food and Drug Administration [8].
As a pre-step for the introduction of direct swab MRSA
molecular detection analysis to our culture based MRSA
surveillance [9], we assessed the use of single and double-
locus rt-PCR, based on previously described assays
[5,7,8]. Here we report the occurrence of false-negative
and false-positive results in two single-locus SCC-
mec:orfX  assays [7,8] and a double locus mecA-Sa442
assay [5].
Methods
Bacterial strains and cultures
The reference strains used for this study were
ATCC33591 (MRSA), ATCC25923 (MSSA), and
ATCC12228 (methicillin-susceptible S. epidermidis
[MSSE]). Other staphylococci strains were all clinical iso-
lates.
Specimen collection and processing
Clinical swab samples were collected from patients
according to a previously defined MRSA infection control
strategy [9] using Amies agar gel swabs (Copan Italia
S.p.a, Brescia, Italy). Swabs were plated on agar plates
(CNA or ChromAgar MRSA [HyLab Ltd., Rehovot,
Israel]), followed by DNA extraction from suspect staph-
ylococci colonies for rt-PCR and identification by con-
ventional culture- techniques [10].
Standard identification and phenotypic susceptibility 
testing of staphylococcal isolates
Staphylococcal isolates were identified morphologically
and biochemically by standard laboratory procedures
[10] discriminating MRSA, MSSA, MR-CoNS, and MS-
CoNS. Screening for oxacillin resistance and other antibi-
otic resistant phenotypes was done following CLSI guide-
lines.
Bacterial lysis and DNA extraction
Template DNA for rt-PCR was extracted using a fast
crude DNA extraction method as previously described
[11]. DNA was extracted from 2-4 overnight colonies.
Aliquots (4-μl) of the extracted DNA were then trans-
f e r r e d  t o  t h e  r t - PC R  r e a c t i o n .  N o  P C R  i n h i b i t i o n  w a s
observed.
rt-PCR assays, primers, and probes
Primers and probes for each assay were described previ-
ously by Reischl [5] Cuny [7] and Huletsky [8]. As Cuny's
assay is a regular PCR assay we used Huletsky's [8] probe
with Cuny's primers. Primers and a probe targeting the
human β-globin gene were added to each assay as an
internal control, validating the absence of PCR inhibition.
Validation assays, screening assays and specificity anal-
yses, were performed in a total volume of 25- μl com-
prised from 4-μl of crude DNA extract, transferred
directly to a 21-μl PCR mixture containing the primers
and probes, 12.5-μl of ABsolute™ QPCR (ABgene, Epsom,
UK) and 0.15-ng human chromosomal DNA (positive at
approximately Ct of 30) using RG-3000 PCR instrument
(Corbett Research, Australia). All runs contained MRSA
control (ATCC33591), MSSA control (ATCC25923), MR-
CoNS control (clinical isolate MRSE) and two NTC con-
trols. The cycling protocol was: 15 min at 95°C, followed
by 40 cycles of 15 s at 95°C, 30 s at 56°C and 15 s at 72°C.
Validation and specificity of the rt-PCR assay
Validation and specificity of the rt-PCR assays were per-
formed in triplicate, using the reference strains
ATCC33591 (MRSA), ATCC25923 (MSSA), and
ATCC12228 (MSSE), and 49 clinical MRSA isolates (10 of
each type I-IV SCCmec and 9 type V SCCmec isolates),
49 MSSA isolates, 25 MR-CoNS isolates and 24 MS-
CoNS isolates.
Validation of clinical MRSA screening rt-PCR assays
A l l  i s o l a t e s  w e r e  a n a l yz e d  f o r  t h e  p r e s e n c e  o f  i n  P C R
mixed bacterial populations. Validation of "unusual"
genotypic strains was performed by a second identical rt-
PCR assay, by agarose gel electrophoresis and by conven-
tional identification. The "unusual" genotypic strains
include:Sa442 negative MSSA, SCC:orfX positive MSSA,
oxacillin-susceptible MRSA (mecA  positive), SCC-
mec:orfX  negative MRSA and oxacillin-resistant MSSA
(mecA negative).
Results
The validation results of the 150 pure culture strains is
presented in Table 1, all internal controls and run con-
trols were identified correctly. As seen in Table 1, one out
of 50 MRSA isolate was misidentified by both Cuny's [7]
and Huletsky's [8] single-locus detection assays. Two out
of 50 MSSA strains were misidentified by both Huletsky's
and Reischl's assays, and 14 out of the 50 MSSA were mis-
identified as MRSAs by Cuny's assay. The results empha-
sized the high percentage (>25%, PPV = 78%) of false
positives using Cuny's [7] assay (Table 1). Consequently,
we decided to continue and assess only the Huletsky's and
Reischl's assays with clinical samples.Kolman et al. BMC Research Notes 2010, 3:110
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During a six-month period, we applied both Huletsky's
and Reischl's assays to 460 suspect staphylococci colo-
nies, recovered from 4097 swabs, in 60 rt-PCR runs. All
samples were also analyzed by conventional methods.
The results are presented in Table 2.
After exclusion of 122 duplicate patients, out of 338
suspect staphylococci colonies analyzed by conventional
identification methods, 219 contained MRSA isolates and
119 were non-MRSA containing isolates. Of these 119
samples, 90 contained MSSA, 16 contained MR-CoNS, 8
contained MS-CoNS and 5 contained non-staphylococ-
cal isolates.
16 and 1 out of 219 MRSAs were misidentified as non-
MRSA by Huletsky's assay and by Reischl's assay, respec-
tively. 13 and 46 out of 119 non-MRSA containing sam-
ples were misidentified as MRSA (false positives) by
Huletsky's assay and by Reischl's assay, respectively. The
diagnostic values of the assays are noted in Table 2. A
detailed description of all the strains, their genotype and
origin is given in the footnotes of Table 2.
The results of the mixed bacterial populations analysis
indicated, that of the 219 MRSA containing samples, 37%
contained also other Gram-positive bacteria, 6% Gram-
negative bacteria and 32% both Gram-positive and
Gram-negative. Of the 90 samples containing MSSA, 42%
also contained other Gram-positive bacteria, 2% Gram-
negative bacteria, and 21% both Gram-positive and
Gram-negative. In addition, MR-CoNS were found in
49% of the MSSA-containing samples. It should be noted
that those percentages do not represent actual percentage
of nasal swabs with mixed populations as many samples
originated from oxacillin containing plates.
Discussion
The major disadvantage of culture based MRSA detec-
tion methods is time constraints which can take 2 to 4
days, during which time carriers can spread MRSA. The
introduction of rapid molecular MRSA detection should
contribute to the prevention of transmission and
improved infection control. The aim of this study was to
evaluate several published rt-PCR assays for MRSA
detection, before introducing direct swab molecular
detection to our MRSA surveillance program [9]. To
eliminate difficulties associated with direct swab analysis
(PCR inhibition, swab extraction protocols, analytical
sensitivities, limits of detection, and logistical difficulties
of swab collection and transport to the laboratory) swab
samples were plated and rt-PCR was done the next day on
S. aureus suspected colonies.
The main disadvantage of double-locus assays is their
inability to differentiate between MRSA and a mixture
c o n t a i n i n g  b o t h  M S S A  a n d  M R - C o N S ,  r e s u l t i n g  i n  a
pseudo-MRSA genotype. Cuny's [7] assay is based on one
forward primer of which at least five of its 3' nucleotides
are within the S. aureus orfX gene (present in MSSA) and
an S. aureus orfX specific reverse primer. Huletsky's [8]
assay is based on a set of five different forward SCCmec-
specific primers, a S. aureus orfX-specific reverse primer
and a set of three S. aureus orfX-specific probes. The
Huletsky assay was the basis for the development of the
first commercial test which has been approved by the U.S.
Food and Drug Administration for MRSA detection [8].
In contrast to the high accuracy observed by Huletsky's
and Reischl's assays when applied on pure cultures, we
observed a high percentage of false positives (specificity =
86 and PPV = 77.8%) when applying Cuny's [7] assay with
Table 1: Validation of pure cultures by single and double-locus detection assays
Real Time PCR results
Pure culture 
strains
Total n = 150
Cuny's [7]
single-locus detectiona
Huletsky's [8]
single-locus detectionb
Reischl's [5]
double-locus detectionc
SCC:orfX+
(MRSA)
SCC:orfX-
(other)
SCC:orfX+
(MRSA)
SCC:orfX-
(other)
Sa442+ 
mec+
(MRSA)
Sa442+ 
mec-
(MSSA)
Sa442- 
mec+
(Oxa. 
resistant)
Sa442- 
mec-
(other)
MRSA (n = 50) 49 1 49 1 50 --- --- ---
MSSA (n = 50) 14 36 2 48 --- 48 --- 2
MR-CoNS (n = 25) --- 25 --- 25 --- --- 25 ---
MS-CoNS (n = 25) --- 25 --- 25 --- --- --- 25
a sensitivity = 98%, specificity = 86%, Positive predictive value = 77.8%, Negative predicted value = 98.9%
b sensitivity = 98%, specificity = 98%, Positive predictive value = 96.1%, Negative predicted value = 99%
c sensitivity = 100%, specificity = 100%, Positive predictive value = 100%, Negative predicted value = 100%Kolman et al. BMC Research Notes 2010, 3:110
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MSSA strains (Table 1). This is probably due to the design
of Cuny's forward primer, which overlaps five of its 3'
nucleotides with S. aureus orfX gene (present in MSSA).
The high false positive rate for MSSA's (>25%) reduces
the likelihood of its use.
We further assessed Huletsky's and Reischl's assays
using clinical samples. A detailed description of all the
strains, their rt-PCR assigned genotype and origin is pre-
sented in Table 2 and its footnotes. As seen in Tables 1
and 2, we isolated several "unusual" genotypic strains,
including 11 Sa442 negative MSSAs, 15 SCC:orfX posi-
tive MSSAs, 2 oxacillin-susceptible MRSA (mecA posi-
tive, Sa442 positive), 17 SCCmec:orfX negative MRSAs
and 1 oxacillin-resistant MSSA (mecA  negative,  Sa442
positive). Work is in progress to further characterize
these strains.
In our point of view, the diagnostic values of both
assays were unsatisfactory for clinical samples. Reischl's
assay displayed low specificity and low positive predictive
value, resulting primarily from pseudo-MRSA mixed
populations. Huletsky's assay displayed unsatisfactory
specificity and unsatisfactory negative predictive value
due to the prevalence of SCCmec:orfX negative MRSAs
and SCC:orfX positive MSSAs. The ability to detect these
strains in an infection control program is crucial. If carri-
ers of SCCmec:orfX negative MRSA's strains are unde-
tected, this strain will spread in the hospital affecting
both the infection control program and the clinical out-
come. The inability to discriminate SCC:orfX  positive
MSSAs from MRSA and MSSA is clinically less critical.
However, the SCC:orfX positive MSSA strain can spread
in the hospital and increasingly affect the whole infection
control program. In addition, based on previous reports,
much lower diagnostic are expected for both assays with
direct swab analysis [6,12,13].
Users of "single-locus" and "double-locus" MRSA detec-
tion assays, both in-house or commercial, applied on
samples containing mixed bacterial populations such as
direct swab analysis, should be aware of the high preva-
lence of false-positive and false-negative reactions, spe-
cifically in hospitals where it is highly likely that a
substantial proportion of the MRSA strains may be clon-
ally related.
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Table 2: Clinical samples results of single and double-locus detection assays
Real Time PCR results
Conventional
culture
identification
(n = 338)
Huletsky's [8]
single-locus detectiona
Reischl's [5]
double-locus detectionb
Combined resultsc
SCC:orfX+
(MRSA)
SCC:orfX-
(other)
Sa442+ 
mec+
(MRSA)
Sa442+ 
mec-
(MSSA)
Sa442- 
mec+
(non S.A 
oxaR)
Sa442- 
mec-
(other)
MRSAd Not MR-
SAe
MRSA (n = 219) 203 16 218 1 --- --- 202 17f
MSSA (n = 90) 13 77 (44+2)g 35 --- 9 1h 89i
MR-CoNS (n = 16) --- 16 --- --- 16 --- 16
MS-CoNS (n = 8) --- 8 --- --- --- 8 8
non-Staph. (n = 5) --- 5 5 5
a sensitivity = 92.7%, specificity = 89.1%, Positive predictive value = 93.4%, Negative predicted value = 86.9%,
b sensitivity = 99.5%, specificity = 61.3%, Positive predictive value = 82.6%, Negative predicted value = 98.6%
c sensitivity = 92.2%, specificity = 99.2%, Positive predictive value = 99.5%, Negative predicted value = 87.4%
d MRSA = SCC:orfX positive, Sa442 positive, mec positive
e Not MRSA = all other results.
f 16 SCC:orfX negative, Sa442 positive, mec positive and 1 oxacillin-resistant MSSA (SCC:orfX positive, Sa442 positive mec negative) classified as 
MRSA by culture methods.
g 44 were MSSA mixed with MR-CoNS, 2 were oxacillin-susceptible MRSA classified as MSSA by culture methods.
h 1 SCC:orfX positive, Sa442 positive, mec positive originated from a mixture of SCC:orfX positive, Sa442 positive, mec negative MSSA and mec 
positive MR-CoNS
i 9 SCC:orfX negative, Sa442 negative, mec negative; 2 SCC:orfX negative, Sa442 positive, mec positive; 22 SCC:orfX negative, Sa442 positive, mec 
negative; 13 SCC:orfX positive, Sa442 positive, mec negative MSSA's and 43 SCC:orfX negative, Sa442 positive, mecKolman et al. BMC Research Notes 2010, 3:110
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